Research advances in chimeric antigen receptor-modified T-cell therapy (Review)

• Published in: Experimental and therapeutic medicine Vol. 21; no. 5; p. 484
• Main Authors: Luo, Yuxi, Song, Guiqin, Liang, Shichu, Li, Feifei, Liu, Kang
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.05.2021; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Antibodies; Antigen receptors, T cell; Antigens; Binding sites; Breast cancer; Cancer; Cancer therapies; Care and treatment; Cell growth; Clinical trials; Cytokines; FDA approval; Glycoproteins; Hematology; Immune system; Immunotherapy; Leukemia; Liver cancer; Lymphoma; Methods; Multiple myeloma; Physiological aspects; Plasma; Receptors; Response rates; Review; Signal transduction; T cells; Tumors; China; chimeric antigen receptor-modified T-cells; adoptive cellular therapy; tumor; immunotherapy
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2021.9915

Chimeric antigen receptor (CAR)-modified T-cells are T-cells that have been genetically engineered to express CAR molecules to target specific surface antigens on tumor cells. CAR T-cell therapy, a novel cancer immunotherapy, has been attracting increasing attention, since it exhibited notable efficacy in the treatment of hematological tumors in clinical trials. However, for this type of therapy, challenges must be overcome in the treatment of solid tumors. Furthermore, certain side effects associated with CAR T-cell therapy, including cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, tumor lysis syndrome and on-target off-tumor toxicity, must be taken into consideration. The present study provides a systematic review of the principle, clinical application, current challenges, possible solutions and future perspectives for CAR T-cell therapy.